Clinical trial · Interventional
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
Hypoxia Assessment in Localized Prostate Cancer: A Companion Protocol to a Phase II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Project Never Initiated - no human subjects were enrolled and no data regarding humans was collected or studied
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as MRI, may help measure oxygen levels in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying how well MRI works in assessing hypoxia in patients with localized prostate cancer undergoing stereotactic body radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood-oxygen-level-dependent functional magnetic resonance imaging | Procedure | — | UNRESOLVED |
| dynamic contrast-enhanced magnetic resonance imaging | Procedure | — | UNRESOLVED |
| magnetic resonance spectroscopic imaging | Procedure | — | UNRESOLVED |
| tissue-oxygen-level-dependent functional magnetic resonance imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Status of global hypoxia within the prostate as assessed by blood-oxygen-level-dependent and tissue-oxygen-level-dependent MRI
- measure
- Tumor vasculature and metabolism within the prostate as assessed by dynamic contrast-enhanced MRI and magnetic resonance spectroscopic imaging
- measure
- Correlation of prostate and normal tissue hypoxia before treatment with clinical outcomes after treatment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy proven adenocarcinoma of the prostate * Localized disease * Scheduled to undergo treatment with stereotactic body radiotherapy (SBRT) on a phase II clinical trial * Has not yet started SBRT PATIENT CHARACTERISTICS: * Serum creatinine ≤ 1.2 mg/dL * No claustrophobia * No other contraindication to MRI (e.g., implanted pacemaker device) * No known allergy to MRI contrast PRIOR CONCURRENT THERAPY: * No prior treatment for prostate cancer (e.g., hormonal therapy or chemotherapy)
References
Publications (0)
Data not yet available